2-chloro-N-(4-chlorophenyl)-6-methylpyrimidin-4-amine | 861032-89-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-(4-chlorophenyl)-6-methylpyrimidin-4-amine
• 英文别名: (2-chloro-6-methyl-pyrimidin-4-yl)-(4-chloro-phenyl)-amine；(2-Chlor-6-methyl-pyrimidin-4-yl)-(4-chlor-phenyl)-amin
• CAS: 861032-89-5
• 化学式: C₁₁H₉Cl₂N₃
• 分子量: 254.119
• InChiKey: SSPJURXDWKWNKS-UHFFFAOYSA-N

物化性质

• 沸点：
  413.7±35.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(4-chlorophenyl)-6-methylpyrimidin-4-amine 在 盐酸 、 水 作用下， 生成 N²-(2-amino-ethyl)-N⁴-(4-chloro-phenyl)-6-methyl-pyrimidine-2,4-diyldiamine
  参考文献：
  名称：

  Curd et al., Journal of the Chemical Society, 1946, p. 720,726

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基-6-(甲基硫代)嘧啶-2-醇 在 三氯氧磷 作用下， 生成 2-chloro-N-(4-chlorophenyl)-6-methylpyrimidin-4-amine
  参考文献：
  名称：

  71.合成抗疟药。第四部分 2-苯基胍基-4-氨基烷基氨基-6-甲基嘧啶

  摘要：

  DOI：

  10.1039/jr9460000362

文献信息

• POTASSIUM CHANNEL MODULATORS
  申请人：Cadent Therapeutics, Inc.

  公开号：US20170355708A1

  公开（公告）日：2017-12-14

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  提供的是公式(I)的新颖化合物： 以及它们的药用可接受盐，这些化合物用于治疗与钾通道相关的一系列疾病、障碍或状况。还提供了包含公式(I)的新颖化合物的药物组合物，它们的药用可接受盐，以及使用它们来治疗与钾通道相关的一种或多种疾病、障碍或状况的方法。
• Synthesis, antimalarial activity, heme binding and docking studies of 4-aminoquinoline–pyrimidine based molecular hybrids
  作者：Deepak Kumar、Shabana I. Khan、Babu L. Tekwani、Prija Ponnan、Diwan S. Rawat

  DOI：10.1039/c4ra09768h

  日期：——

  A series of novel 4-aminoquinoline–pyrimidine hybrids was synthesized and evaluated for their antimalarial activity.

  一系列新颖的4-氨基喹啉-嘧啶杂合物被合成并评估其抗疟活性。
• INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS
  申请人：Eriksen Birgitte L.

  公开号：US20090325989A1

  公开（公告）日：2009-12-31

  This invention relates to novel indazolyl derivatives useful as potassium channel modulating agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, autism, ataxia, traumatic brain injury, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, anxiety, depression, mania, mood disorders, dementia, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, spasticity, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, irritable bowel syndrome, immune suppression, migraine and pain.

  本发明涉及一种新型吲唑基衍生物，作为钾通道调节剂有用，并且它们在制备药物组合物中的使用。此外，该发明针对与钾通道活性相关的疾病或疾病的治疗或缓解，特别是呼吸系统疾病，癫痫，惊厥，失神发作，血管痉挛，冠状动脉痉挛，肾脏疾病，多囊肾病，膀胱痉挛，尿失禁，膀胱出口梗阻，勃起功能障碍，胃肠功能障碍，分泌性腹泻，缺血，脑缺血，缺血性心脏病，心绞痛，冠心病，自闭症，共济失调，创伤性脑损伤，帕金森病，双相情感障碍，精神病，精神分裂症，焦虑，抑郁症，狂躁，情感障碍，痴呆，记忆和注意力缺陷，阿尔茨海默病，肌萎缩性侧索硬化症（ALS），痛经，嗜睡病，雷诺氏病，间歇性跛行，Sjorgren综合症，心律失常，高血压，肌肉肌无力，痉挛，干口症，2型糖尿病，高胰岛素血症，早产，脱发，癌症，肠易激综合征，免疫抑制，偏头痛和疼痛。
• Indazolyl derivatives useful as potassium channel modulating agents
  申请人：Neurosearch A/S

  公开号：US08222262B2

  公开（公告）日：2012-07-17

  Potassium channel modulating agents of Formula Ia or Ib and enantiomers and mixtures enantiomers and N-oxides thereof, and pharmaceutically acceptable salts thereof, and their use in the preparation of pharmaceutical compositions. Also, pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, e.g., respiratory diseases, epilepsy, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, schizophrenia, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, immune suppression, or pain.

  公式Ia或Ib的钾通道调节剂及其对映体、对映体混合物和其N-氧化物，以及其药学上可接受的盐，并用于制备制药组合物。此外，制药组合物可用于治疗或缓解与钾通道活性相关的疾病或疾病，例如呼吸系统疾病，癫痫，惊厥，血管痉挛，冠状动脉痉挛，肾脏疾病，多囊肾病，膀胱痉挛，尿失禁，膀胱出口梗阻，肠易激综合征，胃肠功能障碍，分泌性腹泻，缺血，脑缺血，缺血性心脏病，心绞痛，冠心病，创伤性脑损伤，精神病，精神分裂症，焦虑，抑郁症，痴呆，记忆和注意力缺陷，阿尔茨海默氏病，痛经，嗜睡病，雷诺病，间歇性跛行，Sjorgren综合征，偏头痛，心律失常，高血压，缺席性癫痫，肌萎缩性肌肉营养不良，干口症，2型糖尿病，高胰岛素血症，早产，脱发，癌症，免疫抑制或疼痛。
• WO2008/40753
  申请人：——

  公开号：——

  公开（公告）日：——